Hello! Welcome to the official website of Betta Pharmaceuticals!
Helpline:0571-86130357     Add to Favorites | Online Feedback 中文
新闻中心 / News Center
The Achievement of the “11th, 12th Five-Year Plan” New Drug Research and Development Major Program – The Academic Conference for the 3rd Anniversary of the release of Conmana was held in Hangzhou
Form: betta   Date: 2014-10-25

        On October 25th, themed by “Innovation, Drive, Development”, the achievement of the “11th, 12th Five-Year Plan” new drug research and development major program – The academic conference for the 3rd anniversary of the release of Conmana was held in Hangzhou. More than 500 lung cancer experts from across the country gathered together to discuss the new progress of targeted drugs for lung cancer, talked about multi-disciplinary comprehensive diagnosis and treatment, investigated the innovation in the detecting techniques of biomarker as well as the future of targeted therapy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). China’s authoritative experts in oncology, Academician of Chinese Academy of Sciences, Sun Yan and Yu Jinming, Professor Guan Zhongzhen, Wu Yilong, Wang Changli, Luo Rongcheng, Zhou Qinghua, Lu Shun, and Zhou Caicun and so on, all attended the conference and delivered their keynote speeches.

Prev: Betta Pharmaceuticals received marketing approval of Icotinib indicating for first-line treatment of patients with advanced-stage NSCLC with EGFR mutation
Next: Betta Pharmaceuticals and Xcovery to co-develop a new generation ALK inhibitor